David Matlin Buys 33,333 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) Director David Matlin acquired 33,333 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was acquired at an average price of $6.50 per share, with a total value of $216,664.50. Following the transaction, the director owned 477,824 shares in the company, valued at approximately $3,105,856. The trade was a 7.50% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Clene Stock Performance

Shares of CLNN stock opened at $5.12 on Thursday. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The stock has a market capitalization of $55.55 million, a PE ratio of -1.51 and a beta of 0.87. The stock’s fifty day moving average is $7.31 and its 200-day moving average is $6.45.

Clene (NASDAQ:CLNN) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. As a group, analysts forecast that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CLNN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. D. Boral Capital reissued a “buy” rating and issued a $23.00 target price on shares of Clene in a research note on Friday, January 9th. Benchmark restated a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Finally, UBS Group reiterated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp acquired a new stake in shares of Clene during the third quarter worth $29,000. Jane Street Group LLC bought a new position in Clene during the second quarter worth about $47,000. Lunt Capital Management Inc. grew its position in shares of Clene by 71.2% during the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after buying an additional 21,217 shares during the period. Finally, Scoggin Management LP increased its stake in shares of Clene by 42.8% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after acquiring an additional 42,750 shares during the last quarter. Institutional investors and hedge funds own 23.28% of the company’s stock.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).